Nab‐paclitaxel in older patients with non–small cell lung cancer who have developed disease progression after platinum‐based doublet chemotherapy-Reference-Cited by-同舟云学术

Nab‐paclitaxel in older patients with non–small cell lung cancer who have developed disease progression after platinum‐based doublet chemotherapy

Published:2020-01-14 Issue:5 Volume:126 Page:1060-1067
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Weiss Jared M.¹^ORCID,Pennell Nathan²,Deal Allison M.¹,Morgensztern Daniel³,Bradford Daniel S.⁴,Crane Jeffrey⁵,West Howard Jack⁶,Lee Carrie¹,Pecot Chad¹,Stevenson James P.²,Irvin William⁷,Socinski Mark⁸,Stinchcombe Tom⁹^ORCID,Villaruz Liza C.¹⁰,Muss Hyman B.¹

Affiliation:

1. Department of Hematology and Oncology Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Chapel Hill North Carolina

2. Hematology and Medical Oncology Cleveland Clinic Cleveland Ohio

3. Oncology Division Department of Medicine Washington University School of Medicine in St. Louis St. Louis Missouri

4. Highlands Oncology Fayetteville Arkansas

5. Rex Hematology Oncology Associates Raleigh‐Durham North Carolina

6. Department of Medical Oncology Swedish Cancer Institute Seattle Washington

7. Medical Oncology Bon Secours Midlothian Virginia

8. Florida Hospital Cancer Institute Orlando Florida

9. Division of Medical Oncology Duke Cancer Institute Duke University School of Medicine Durham North Carolina

10. Division of Hematology/Oncology University of Pittsburgh Medical Center Hillman Cancer Center Pittsburgh Pennsylvania

Funder

Celgene

Publisher